Windmill Will Be Initially Placing GelStat Migraine in 200 Independent Pharmacies Throughout the Northeast
PALM CITY, FL -- (Marketwired) -- 01/27/14 -- GelStat Corporation (PINKSHEETS: GSAC), a company engaged in the research, development, marketing and branding of innovative Over-the-Counter (OTC) consumer healthcare products, is pleased to announce today that it has received the initial purchase order from Windmill Health Products. Windmill serves over 3,000 independent pharmacies and is initially placing Gelstat Migraine in 200 independent pharmacies throughout the northeast.
Bruce Burns, Senior Vice President at Windmill, said, "They have had success over the years distributing a number of natural homeopathic products and look forward to working with GelStat in this much needed migraine pain category."
Larry Gershman, GelStat's CEO, said, "I'm thrilled to be working with Windmill Health Products and its sales team to distribute GelStat's products into select retailers. We hope this is the beginning of a long and prosperous relationships with one of the largest and most respected companies in the industry."
Make sure you are first to receive timely information on GelStat Corporation when it hits the newswire. Sign up for GelStat's email news alert system today at: https://ir.stockpr.com/gelstat/request-information
Windmill has been providing pharmacies and their clients with the finest in nutritional supplementation for over 40 years. Windmill now serves over 3,000 independent pharmacies exclusively with the Windmill branded line of vitamins, supplements and products for a healthy lifestyle, plus all of the services required for successful front-end vitamin merchandising including: circulars, price stickers, promotional calendars, company-supported sale events, point-of-sale and point-of-purchase materials and consistent one-on-one field support and professional, knowledgeable field and home office services.
In addition, Windmill serves a variety of other retail venues including club, food, drug, mass market, health food and others -- providing the most innovative and highly visible supplement products at retail in over 100,000 outlets, across all categories, including health, weight loss, specialized health, skin care and many others, as well as partnering with our clients to provide customized products for individualized consumer need in select markets.
ABOUT GELSTAT CORPORATION
GelStat Corporation is a publicly traded company trading under the symbol ("GSAC") that is engaged in research, development, marketing and branding of innovative over-the-counter (OTC) consumer healthcare products addressing very large markets. The Company's initial products include GelStat Migraine, GelStat Sleep, Chews 2 Lose and All Natural Speed. The Company also has a suite of additional healthcare products in various stages of development that address large consumer markets.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, expects the market for migraine therapies to grow from $3.3 billion in 2011 to $5.8 billion in 2021 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
The total over-the-counter market for sleep aids alone reached $604 million in 2008, an increase of 9 percent over 2007, according to Packaged Facts, a division of Rockville, Md.-based Market Research Group.
According to Marketdata Enterprises, Inc., a leading independent market research publisher of "off-the-shelf" studies about service industries since 1979, an estimated 75 million dieters spent $2.7 billion in 2010 on diet pills and meal replacements.
According an article published by Companies and Markets.com, the US energy drinks market is estimated to have increased by 60% over the past four years, hitting an estimated value of $12.5 billion in 2012. The industry is expected to continue this growth path, by rising to a valuation of $21.5 billion by 2017.
For more information, visit www.gelstat.com.
Safe Harbor Statement
This press release and the shareholder letter contains forward-looking statements including pursuing strategic relationships, building and leveraging a direct-to consumer platform to launch new products, acquiring or licensing the rights to products with proven science, growing organically and achieving each of the goals mentioned above. Forward-looking statements can be identified by words such as "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects" and similar references to future periods.
Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the failure of our products to be accepted, failure to obtain partners to market and distribute our products, unanticipated delays in launching website or failure of the website to generate revenues, our inability to find a target to acquire on mutually acceptable terms, and the inability to get our reports prepared and filed timely as a result of unforeseen audit issues.
Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
FOR ADDITIONAL INFORMATION CONTACT:
Source: GelStat Corporation